TrialBritish journal of cancer2023

A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer.

Valentine M Macaulay et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.